COMPANY ANNOUNCEMENT - No. 4-2024 -
BIRKERØD,
Reference is made to company announcement no. 02-2024 of
The following resolutions were passed:
- Attorney-at-law
Jens Folker-Bruun was elected chairman of the general meeting. - The general meeting approved the board’s report on the company’s business for 2023.
- The annual report was approved.
-
It was resolved to transfer the loss for the financial year 2023 of
DKK -12,096,105 to the following year. - An indicative vote approved the remuneration report.
Patrik Dahlen ,Lars Kongsbak andValérie Soulier were re-elected as board members.-
It was resolved that the annual remuneration fee for the board’s work in 2024 will remain unchanged at
DKK 150,000 for the chairman andDKK 75,000 for each of the other directors. BDO Statsautoriseret Revisionsaktieselskab was re-elected as auditor for the company.- The proposal for amending Articles 2.3 and 2.3.1 was approved.
- The proposal to authorize the Chairman of the meeting (with substitution rights) to register the decisions was approved.
- Nothing related to this point on the agenda was resolved.
The announcement can be found at https://www.virogates.com/investor/announcements
For further information, please contact:
CEO,
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About
The company was founded in 2000. Headquartered in
About suPAR and suPARnostic®
suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 1000 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in triage in emergency departments can identify patients in low risk of disease progression (supports discharge) and high risk patients that can benefit from early treatment to lower the risk of disease progression. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas® instruments, Siemens Healthineers ADVIA® XPT and Atellica® instruments, the Abbott Labs Architect™ and Alinity™ instruments and the Beckmann Coulter AU 5800 instrument.
Disclosure regulation
Prospects about the future reflect
Contacts
Jakob Knudsen , CEO, +45 2226 1355, jk@virogates.com
Attachments
- 20240425-Company Announcement 4 - AGM resolutions.pdf
© Ritzau Denmark, source